Durham said that he voted no because of poor characterization of the compound and the potential risk with carcinogenicity. William Zamboni, a pharmacologist at the University of North Carolina said that he voted no because he felt there was a significant lack of data on the safety of the product.
Deeper set wrinkles improve more slowly
Injection site reactions including minor redness, itching, or irritation occur occasionally
In the renal system, OS has been implicated both in renal injury and in increasing the risk of complications, including impaired therapeutic responses (e.g., corticosteroid resistance)
BPC-157 Dosage Protocol by Use Case As someone whos been using and recommending BPC-157 for decades, here is the practical framework I share in Living A Fully Optimized Life and the rest of my books and courses: Acute Injuries (Muscle Tears, Tendon Damage, Ligament Strains) 250500 mcg subcutaneously, twice daily (once in the morning and once in the evening) Dosing near the site of injury may provide additional local benefit, though the compound distributes systemically regardless of injection location